These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 6777018)

  • 1. Plasma exchange and human factor VIII concentrate in managing haemophilia A with factor VIII inhibitors.
    Wensley RT; Stevens RF; Burn AM; Delamore IW
    Br Med J; 1980 Nov; 281(6252):1388-9. PubMed ID: 6777018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
    CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factor VIII:C and VIII:CAg response in patients with haemophilia A and von Willebrand's disease after administration of different factor VIII concentrates or plasma.
    Holmberg L; Borge L; Nilsson IM
    Br J Haematol; 1981 Apr; 47(4):587-96. PubMed ID: 6783063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An inhibitor to factor VIII:C in a patient with possible combined haemophilia A and von Willebrand's disease.
    Taylor LD; Dean FL; Tiedemann K; Ekert H
    Thromb Haemost; 1986 Apr; 55(2):158-61. PubMed ID: 3087000
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
    Janković GM; Janosević S
    Haematologia (Budap); 1978-1979; 12(1-4):183-8. PubMed ID: 317061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quantitative assay of a plasma factor deficient in von Willebrand's disease that is necessary for platelet aggregation. Relationship to factor VIII procoagulant activity and antigen content.
    Weiss HJ; Hoyer LW; Rickles FR; Varma A; Rogers J
    J Clin Invest; 1973 Nov; 52(11):2708-16. PubMed ID: 4542944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P): in von Willebrand disease and haemophilia A.
    Carter NJ; Scott LJ
    Drugs; 2007; 67(10):1513-9. PubMed ID: 17600395
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to infusions of polyelectrolyte fractionated human factor VIII concentrate in human haemophilia A and von Willebrand's disease.
    Tuddenham EG; Lane RS; Rotblat F; Johnson AJ; Snape TJ; Middleton S; Kernoff PB
    Br J Haematol; 1982 Oct; 52(2):259-67. PubMed ID: 6812613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Factor VIII in hemophilia and von Willebrand's disease].
    Bolland J; Lambotte C
    Rev Med Liege; 1978 Apr; 33(8):284-95. PubMed ID: 349657
    [No Abstract]   [Full Text] [Related]  

  • 11. Stabilization of factor VIII in plasma by the von Willebrand factor. Studies on posttransfusion and dissociated factor VIII and in patients with von Willebrand's disease.
    Weiss HJ; Sussman II; Hoyer LW
    J Clin Invest; 1977 Aug; 60(2):390-404. PubMed ID: 17621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequency and clinical and transfusional significance of rheumatoid factor in patients with haemophilia and von Willebrand's disease.
    Celada A; Aguado MT; Ortega F; Magallon M; Martin-Villar J; Lambert PH
    Vox Sang; 1984; 47(4):271-5. PubMed ID: 6333107
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of plasma and/or factor VIII concentrates administration on platelet functions in patients with haemophilia A and von Willebrand's disease (author's transl)].
    Gamba G; Grignani G; Nicolini E; Ascari E
    Haematologica; 1975 Jun; 60(2):168-83. PubMed ID: 808449
    [No Abstract]   [Full Text] [Related]  

  • 14. Human plasma von Willebrand factor/factor VIII complex (Haemate P/Humate-P) in von Willebrand disease and haemophilia A: a viewpoint by Eric Berntorp.
    Berntorp E
    Drugs; 2007; 67(10):1520. PubMed ID: 17600396
    [No Abstract]   [Full Text] [Related]  

  • 15. Correction by factor VIII of decreased neutrophil alkaline phosphatase activity in classic haemophilia and von Willebrand's disease.
    Janković GM
    Thromb Res; 1979; 16(3-4):557-64. PubMed ID: 316208
    [No Abstract]   [Full Text] [Related]  

  • 16. Nature of haemophilia and von Willebrand's disease.
    Ekert H; Muntz RH
    Aust N Z J Med; 1974 Feb; 4(1):66-70. PubMed ID: 4602351
    [No Abstract]   [Full Text] [Related]  

  • 17. [Inactive factor VIII in hemophilia A and Willebrand's disease].
    Lechner K
    Verh Dtsch Ges Inn Med; 1972; 78():710-3. PubMed ID: 4541862
    [No Abstract]   [Full Text] [Related]  

  • 18. Absence of anti-human immunodeficiency virus types 1 and 2 seroconversion after the treatment of hemophilia A or von Willebrand's disease with pasteurized factor VIII concentrate.
    Schimpf K; Brackmann HH; Kreuz W; Kraus B; Haschke F; Schramm W; Moesseler J; Auerswald G; Sutor AH; Koehler K
    N Engl J Med; 1989 Oct; 321(17):1148-52. PubMed ID: 2507917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The use of plasma fractions in the treatment of hemophilia and von Willebrand's disease.
    Rizza CR; Biggs R
    Prog Hematol; 1969; 6():181-200. PubMed ID: 4889322
    [No Abstract]   [Full Text] [Related]  

  • 20. Control of life-threatening bleeding by combined plasmapheresis and immunosuppressive treatment in a haemophiliac with inhibitors.
    Révész T; Mátyus J; Goldschmidt B; Harsanyi V
    Arch Dis Child; 1980 Aug; 55(8):641-3. PubMed ID: 6776907
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.